{"nctId":"NCT00477607","briefTitle":"Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin","startDateStruct":{"date":"2007-10"},"conditions":["Ototoxicity","Unspecified Adult Solid Tumor"],"count":39,"armGroups":[{"label":"Arm 1","type":"EXPERIMENTAL","interventionNames":["Drug: alpha-lipoic acid","Behavioral: Audiology","Biological: laboratory biomarker analysis"]},{"label":"Arm 2","type":"PLACEBO_COMPARATOR","interventionNames":["Behavioral: Audiology","Biological: laboratory biomarker analysis","Drug: Placebo"]}],"interventions":[{"name":"alpha-lipoic acid","otherNames":["lipoic acid"]},{"name":"Audiology","otherNames":["ototoxicity monitoring"]},{"name":"laboratory biomarker analysis","otherNames":["MDA"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of cancer\n* Receiving therapeutic treatment with cisplatin\n* Fertile patients must use effective contraception during and for 3 months after completion of study treatment\n* Cognitively and physically able to participate in the study\n* Must be able to provide reliable behavioral threshold responses (patient must meet intra-session reliability criterion of +/- 5 dB)\n* At least 6 months since prior treatment with cisplatin or other ototoxic medications (e.g., aminoglycoside antibiotics)\n* At least 6 months since prior and no concurrent radiotherapy for head and neck tumors\n* Concurrent radiotherapy targeted below the neck allowed\n* More than 1 month since prior alpha-lipoic acid supplements\n\nExclusion Criteria:\n\n* No aggressive behavior as indicated in electronic chart notes\n* No documented dementia\n* No Alzheimer's disease\n* No severe psychosocial disorder\n* No active or recent history of middle ear disorder based on otoscopy, tympanometry, immittance, or notes in patient chart\n* No renal disease\n* No Meniere's disease or retrocochlear disorder based on patient report or notes in patient's chart\n* Not receiving treatment for diabetes mellitus\n* No concurrent vincristine or vinblastine\n* No other concurrent investigational therapy\n* No other concurrent antioxidants or vitamin E \\> 100 IU per day","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Ototoxicity Measurement","description":"Any American Speech and Hearing Association (ASHA)-significant hearing loss in the Sensitive Region for Ototoxicity frequencies between baseline measurement and any follow-up measurement.\n\nASHA criteria are defined as\n\n* 20 decibel (dB) increase at any test frequency,\n* 10 dB increase at any two consecutive test frequencies, or loss of response where there was previously a response at any three test frequencies.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Malondialdehyde (MDA) Levels","description":"Computed maximum increase relative to baseline for each subject = (max MDA during treatment) - baseline MDA level.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":"1.00"},{"groupId":"OG001","value":"0.47","spread":"0.83"}]}]}]},{"type":"SECONDARY","title":"Total Amount of Prescribed Cisplatin Dose Administered","description":"Maximum cumulative dose of cisplatin (mg/m\\^2) administered during the course of chemotherapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"239.7","spread":"92.6"},{"groupId":"OG001","value":"191.5","spread":"110.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":19},"commonTop":["Small bowel obstruction","Spine pain","Distended abdomen","Atrial Fibrillation","Muscle Weakness"]}}}